Is the genetic evidence behind your drug target still true?
CohortLayer is an independent, repeatable audit of the human genetic evidence behind a drug target. You give us a target, an indication and a direction of effect. We return an evidence dossier that says what holds, what has weakened and what conflicts, and we re-run it when the evidence changes.
For biotech, techbio, investor and translational teams making high-stakes target decisions.
What does the dossier answer?
- 01
Do the published claims still hold?
Each claim is rated: confirmed, weakened, conflicting or untested. - 02
Does the direction of effect match your mechanism?
An association is not enough. What matters is whether lowering the gene's activity helps or harms. - 03
What safety signals appear for the same gene?
Other traits and conditions linked to the same gene, so on-target risks surface before the clinic. - 04
What changed since the last version?
Every dossier is versioned. When the evidence moves, you see what changed and whether the verdict moved with it.
Why does this matter?
Targets with human genetic support are more than twice as likely to reach approval. Most teams check that support once, against one dataset, and never revisit it. Evidence keeps moving after the check is done. (Nelson et al., Nature Genetics 2015; Minikel et al., Nature 2024)
Fewer than 1 in 8 drugs entering clinical trials are ever approved. (Wouters et al., JAMA 2020)